Trial Search Results

Efficacy and Safety of ALGRX 3268 in Children Undergoing Minor Needle-Stick Procedures.

Minor needlestick procedures often cause significant pain and distress in pediatric patients yet interventions to reduce pain are used infrequently. ALGRX 3268 is a novel, single-use, prefilled, needle-free product that immediately delivers powdered lidocaine into the epidermis and provides local analgesia in 2-3 minutes. The purpose of this phase III, prospective, randomized, double-blind, placebo-controlled study is to investigate the efficacy, safety and tolerability of ALGRX 3268 versus placebo in pediatric patients aged 3 to 18 years undergoing venipuncture or peripheral venous canulation procedures. The trial will enroll approximate 504 evaluable subjects at centers located in the US.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

AlgoRx Pharmaceuticals

Stanford Investigator(s):

Intervention(s):

  • Drug: ALGRX 3268

Phase:

Phase 3

Eligibility


Inclusion Criteria:

   - Outpatient children of either gender [M/F: 1:1] undergoing venipuncture or peripheral
   venous cannulation at the ATF or BOH. Children must have sufficient cognitive skills
   to identify faces depicting extremes of pain on the Wong-Baker FACES Pain Rating
   Scale, (ages 3-12) and/or the extremes of pain on a 100 VAS (ages 8-18).

   - Ages 3-7, 8-12, 13-18 years inclusive. Informed consent forms must have been approved
   by the appropriate IRB. Signed informed consent must have been granted by the
   parent/legal guardian and assent to participate should have been sought (either
   verbally or in writting) from each child.

   - In females of childbearing potential who in the judgement of the investigator or
   designee were sexually active, a negative preganancy test must have been documented
   prior to enrollment. A negative urine preganancy test was required in all teenage
   girls over the age of 14 years. Surgically sterile females do not require a pregnancy
   test.

Exclusion Criteria:

   - Previous history of allergic reactions to any local anesthetic. Any medical condition
   or instability that in the judgement of the investigator might have adversely impacted
   the conduct of the study and the collection of data.

   - Subjects in whom the investigator determined that venipuncture could not be
   accomplished cleanly.

   - Active local infection or other skin pathology on the dorsum of the hand. Subjects
   with tattos, surgical scars, ports, implantable devices or a skin condition that may
   have interfered with placement of study treatment or skin site assessments.

   - Female subjects who were pregnant or lactating; females with a positive serum or urine
   pregnancy test; females of childbearing potential who were not using adequate
   contraception.

   - Prior participation in an ALGRX 3268 study.

   - Venipuncture at the proposed site within the prior 2 weeks (longer if bruising was
   apparent).

Ages Eligible for Study

3 Years - 18 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting